Global /United States /Healthcare /Medical Devices /VANI

Vivani Medical, Inc.

VANI

• NASDAQ: VANI • Delayed

1.32USD -3.7%

As of 13 June 2026, Vivani Medical, Inc. has a market cap of $111.74M USD, ranking #24767 globally and #3836 in the United States. It ranks #2211 in the Healthcare sector, and #456 in the Medical Devices industry.

Global Rank

24767

Country Rank

3836

Sector Rank

2211

Industry Rank

456

Key Stats

Market Cap

$111.74MUSD

Enterprise Value

$114.36MUSD

EBITDA (TTM)

-$27.13MUSD

Net Income (TTM)

-$26.61MUSD

PB Ratio

6.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Medical Devices

CEO

Adam Mendelsohn open_in_new

Employees

Founded

1998

IPO

19 Nov 2014

Website

vivani.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.7%	-0.8%	29%	-11%	-21%	7.3%	26%	19%	-94%

News

VANI Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	VANI Vivani Medical Inc ISIN: US92854B1098 Shares Out.: Shares Outstanding: 86.235M¹ Shares Float: 41.054M² TV: TradingView: NASDAQ: VANI SA: Stock Analysis: NASDAQ: VANI YF: Yahoo Finance: VANI GF: Google Finance: NASDAQ: VANI NQ: NASDAQ: VANI BA: Barron's: VANI MS: Morningstar: XNAS: VANI	1.32 USD	TV: TradingView: NASDAQ: VANI SA: Stock Analysis: NASDAQ: VANI YF: Yahoo Finance: VANI GF: Google Finance: NASDAQ: VANI NQ: NASDAQ: VANI BA: Barron's: VANI MS: Morningstar: XNAS: VANI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Vivani Medical, Inc.

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.

Similar Companies

Industry: Medical Devices (United States)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 155K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 144K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 142K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 113K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 108K%	38.3	United States
Boston Scientific Corp. NYSE: BSX	$84.93B 76K%	24.5	United States

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Medtronic plc NYSE: MDT	$101.9B 91K%	22.2	Ireland
EssilorLuxottica Société anonyme EPA: EL	$97.46B 84.32B EUR 87K%	36.7	France
HOYA Corp. TSE: 7741	$61.41B 9.83T JPY 55K%	40.0	Japan
Siemens Healthineers AG XETRA: SHL	$45.47B 39.34B EUR 41K%	18.7	Germany
Alcon Inc. SIX: ALC	$36.38B 28.99B CHF 32K%	37.9	Switzerland
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. SHE: 300760	$30.06B 203.66B CNY 27K%	26.0	China

chevron_leftBack